| abstract |
An aqueous pharmaceutical formulation comprising denosumab or another human anti-RANKL (nuclear factor kappa-B ligand) monoclonal antibody or a portion thereof. An aqueous pharmaceutical preparation comprising (i) a human anti-human receptor activator of a nuclear factor kappa-B ligand (anti-RANKL) monoclonal antibody or an antigen-binding portion thereof, and (ii) an amino acid aggregation inhibitor. The amino acid aggregation inhibitor includes an amino acid containing a charged side chain, an aromatic amino acid, or a hydrophobic amino acid. [Selection] Figure 1 |